Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the Icahn School of Medicine at Mount Sinai. The antidepressant benefits of ketamine were seen within 24 hours, whereas traditional antidepressants can take days or weeks to demonstrate a reduction in depression.

The research was discussed at the American Psychiatric Association meeting on Monday, May 20.

Read here the full article.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.